tradingkey.logo
搜索

PharmaCyte Biotech Inc

PMCB
添加自选
0.715USD
-0.026-3.51%
收盘 07/02, 13:00美东报价延迟15分钟
7.68M总市值
亏损市盈率 TTM

PharmaCyte Biotech Inc

0.715
-0.026-3.51%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-3.51%

5天

-7.11%

1月

-1.43%

6月

-3.12%

今年开始到现在

-1.24%

1年

-35.59%

关键数据
0.756今开
0.770最高
55.65K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.52%换手率
0.741昨收
0.715最低
34.15K成交额
0.33市盈率静
0.20市净率
0.00%股息率 TTM
-6.58%ROA
1.51052周最高
1.20量比
23.36M净利润
10.74M总股本
-0.8906每股收益TTM
0.50Beta
-19.01%ROE
0.63052周最低
7.42%振幅
--毛利率
7.68M总市值
0.38回报/风险
5.59%风险率

TradingKey PharmaCyte Biotech Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

PharmaCyte Biotech Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名219/387位。机构持股占比非常高,中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

PharmaCyte Biotech Inc评分

相关信息

行业排名
219 / 387
全市场排名
439 / 4565
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

PharmaCyte Biotech Inc亮点

亮点风险
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
业绩转盈
公司业绩转盈,最新年度盈利美元
估值合理
公司最新PE估值-0.80,处于3年历史合理位
机构加仓
最新机构持股1.07M股,环比增加24.50%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值0.00

分析师目标

根据 0 位分析师
--
评级
--
目标均价
--
涨幅空间

PharmaCyte Biotech Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

PharmaCyte Biotech Inc简介

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
公司代码PMCB
公司PharmaCyte Biotech Inc
CEOSilverman (Joshua N)
网址https://pharmacyte.com/

常见问题

PharmaCyte Biotech Inc(PMCB)的当前股价是多少?

PharmaCyte Biotech Inc(PMCB)的当前股价是 0.71。

PharmaCyte Biotech Inc的股票代码是什么?

PharmaCyte Biotech Inc的股票代码是PMCB。

PharmaCyte Biotech Inc股票的52周最高点是多少?

PharmaCyte Biotech Inc股票的52周最高点是1.51。

PharmaCyte Biotech Inc股票的52周最低点是多少?

PharmaCyte Biotech Inc股票的52周最低点是0.63。

PharmaCyte Biotech Inc的市值是多少?

PharmaCyte Biotech Inc的市值是7.68M。

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是多少

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是3.19。